Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2011 May 12;286(27):23771–23779. doi: 10.1074/jbc.M111.251116

An Akt-dependent Increase in Canonical Wnt Signaling and a Decrease in Sclerostin Protein Levels Are Involved in Strontium Ranelate-induced Osteogenic Effects in Human Osteoblasts*

Mark S Rybchyn , Michael Slater , Arthur D Conigrave §, Rebecca S Mason ‡,1
PMCID: PMC3129158  PMID: 21566129

Abstract

Sclerostin is an important regulator of bone homeostasis and canonical Wnt signaling is a key regulator of osteogenesis. Strontium ranelate is a treatment for osteoporosis that has been shown to reduce fracture risk, in part, by increasing bone formation. Here we show that exposure of human osteoblasts in primary culture to strontium increased mineralization and decreased the expression of sclerostin, an osteocyte-specific secreted protein that acts as a negative regulator of bone formation by inhibiting canonical Wnt signaling. Strontium also activated, in an apparently separate process, an Akt-dependent signaling cascade via the calcium-sensing receptor that promoted the nuclear translocation of β-catenin. We propose that two discrete pathways linked to canonical Wnt signaling contribute to strontium-induced osteogenic effects in osteoblasts.

Keywords: Akt PKB, β-Catenin, Bone, Signal Transduction, Wnt Pathway, Calcium Sensing Receptor, PI3K, Sclerostin, Strontium

Introduction

Strontium ranelate is a treatment for osteoporosis that decreases the incidence of vertebral and femoral fracture risk in postmenopausal women (13). Strontium ranelate has been shown to modulate the physiological processes of bone formation and bone resorption (2), resulting in increased bone apposition rates (3) and bone mineral density (1, 2, 46), while maintaining the quality of bone mineral (6).

Sclerostin is exclusively expressed by osteocytes in adult life (7, 8) but is more widely expressed during development (7) and plays a physiological role as a negative regulator of bone formation by repressing bone morphogenic protein-induced osteogenesis (911). The importance of sclerostin in bone-loss disorders has been described in several in vivo studies. Positional cloning studies identified loss of function mutations in the SOST gene that cause sclerostosis and van Buchem disease, bone dysplasias characterized by progressive skeletal overgrowth (12). In contrast, transgenic mice overexpressing sclerostin had significant reductions in bone mass and mineral apposition rate compared with wild type (7). A sclerostin knock-out mouse model was shown to have increased osteoblast activity and enhanced osteoblast/osteocyte viability and was resistant to mechanical unloading-induced bone loss. This phenotype was associated with an increase in canonical Wnt signaling when compared with wild-type mice (8).

Sclerostin functions as an antagonist of canonical Wnt signaling, whereby GSK-3β2-stimulated, ubiquitin-mediated breakdown of β-catenin is alleviated, resulting in its nuclear translocation, and binding to transcription factors of the T-cell factor/lymphoid enhancer factor family, to induce the transcription of growth-associated genes (13). Non-canonical Wnt signaling does not involve β-catenin translocation to the nucleus (11). Sclerostin binds to the extracellular domains of the Wnt co-receptors LRP5, LRP6, and LRP4 and disrupts extracellular Wnt-induced Frizzled/LRP complex formation thus providing a molecular mechanism by which loss of sclerostin function may lead to conditions such as sclerostosis (12, 14). In addition to Frizzled/LRP-mediated activation of canonical Wnt signaling, β-catenin also translocates to the nucleus following phosphorylation by Akt at Ser552 (15) and in response to Akt-mediated deactivation of GSK-3β at Ser9 (16). This Akt-signaling mechanism represents an alternative activation pathway for canonical Wnt signaling. The mammalian target of rapamycin (mTOR) complex 2 (mTORC2) has been shown to be the upstream kinase responsible for Akt phosphorylation at Ser473 (17), whereas mTOR complex 1 (mTORC1) lies downstream of Akt (18) and responsible for the control of p70 S6 kinase (19). Although mTORC2 activation arises in response to a variety of stimulatory factors (20), the mechanism is unclear.

We and others have previously reported that treatment of primary human osteoblasts with strontium increases replication as well as expression of differentiation markers RUNX2 and alkaline phosphatase (2123). These results complement in vivo studies in animals (24) and human subjects (6), which show increases in bone formation after treatment with strontium ranelate. Because stimulation of the canonical Wnt pathway is also osteogenic in vivo (25) we investigated whether strontium ranelate affected canonical Wnt signaling in primary human osteoblasts.

EXPERIMENTAL PROCEDURES

Materials

All chemicals, including culture media and fetal calf serum (FCS) were obtained from Sigma-Aldrich unless otherwise specified. Sodium ranelate was supplied by Les Laboratories Servier (Neuilly, France). ThermanoxTM coverslips were obtained from Thermo Fisher Scientific (Rochester, NY). Opti-MEMTM was obtained from Invitrogen. Antibodies were obtained as follows: β-catenin-Ser552, Akt, Akt-Ser473, Akt-Thr308, GSK-3β, and GSK-3β-Ser9 monoclonal antibodies were obtained from Cell Signaling Technology (Danvers, MA), a sclerostin monoclonal antibody, a sclerostin biotinylated polyclonal antibody, recombinant human sclerostin were obtained from R&D Systems (Minneapolis, MN), and β-actin and β-catenin monoclonal antibodies were obtained from Sigma-Aldrich. The bicinchoninic acid (BCA) assay was obtained from Thermo Scientific (Rockford, IL). The Akt kinase inhibitor AKT-XI was obtained from Merck KGaA (Darmstadt, Germany). The NPS2143 calcilytic was kindly donated by Dr. Arthur Christopoulos. All absorbance and fluorescence measurements were carried out on a Polarstar Galaxy plate reader (BMG Labtech GmbH, Offenburg, Germany).

Methods

HOB Culture Conditions

Human osteoblasts (HOB) were grown from the minced trabecular ends of fetal long bone in accordance with the National Health and Medical Research Council guidelines and with the approval of the University of Sydney Human Ethics Committee (approval number: 01/02/40), as described previously (26). The study was conducted using HOBs from several different donors. Each experiment was conducted using HOBs from at least two different donors. HOBs were routinely maintained in DMEM containing 10% (v/v) FCS supplemented with 150 μm l-ascorbic acid 2-phosphate (10% DMEM) and were plated in 6-well plates at 5 × 105 HOBs/well for all experiments. HOBs were treated in serum-reduced Opti-MEMTM media (Invitrogen) containing 1 mm Ca2+ (defined as the “Vehicle” treatment for all experiments, to approximate the concentration of physiological Ca2+ for humans (27) with the addition of strontium ranelate at various concentrations as described for the individual experiments. For all experiments HOBs were adapted to the vehicle treatment for 3 h prior to the addition of strontium ranelate. For the purposes of this study, strontium ranelate consisted of a 100:1 molar ratio of Sr2+, derived from SrCl2, and ranelate, sourced from sodium ranelate, because this ratio reflects the relative concentrations of strontium and ranelic acid in the serum of patients treated with strontium ranelate 2 g/day for 3 years. Previous studies have shown that Sr2+ is the active agent (28). Concentrations of strontium ranelate used in this study are expressed in terms of Sr2+ (millimolar). The concentrations of strontium ranelate used for treatment of HOBs in this study were 0.1 mm, intended to mimic the approximate strontium blood concentration of patients treated with strontium ranelate 2 g/day (29), and 2 mm, which may reflect increased strontium concentrations that may be present at sites of bone remodeling (30).

To permit HOBs to grow into a multilayer structure the cells were subcultured into 6-well plates containing ThermanoxTM coverslips and grown using an adaptation of a previously established protocol (26). Briefly, cells were grown to confluence in 10% DMEM and the media was then changed to mineralization medium (Opti-MEMTM containing 2.5% (v/v) FCS, 2.5 mm β-glycerophosphate, and 150 μm l-ascorbic acid 2-phosphate, 100 units/ml penicillin, and 100 μg/ml streptomycin) with the addition of strontium ranelate for the indicated duration and concentration as described for the individual experiments. Mineralization media were routinely changed every 2 days for the course of the experiment.

Quantification of Mineralization

Alizarin Red S (ARS) was used to quantify the mineralization of HOB cultures in response to strontium ranelate treatment using an adaptation of a previously established protocol (31). Briefly, HOBs were grown to confluence on ThermanoxTM as previously described and then grown for a further 7 or 14 days in mineralization media in the presence or absence of strontium ranelate at the indicated concentration. Following treatment, mineralized HOBs were washed three times with PBS and fixed with 70% (v/v) ice-cold ethanol for 1 h. The fixed layers were washed three times with excess dH2O prior to the addition of 2% (w/v) ARS (pH 4.2) for 30 min at room temperature with gentle agitation. Following removal of ARS the stained layers were washed five times for 5 min with excess dH2O, and three times with PBS for 5 min at room temperature. Mineral-bound ARS was solubilized by the addition of 1 ml of 10% (w/v) cetylpyridium chloride in 10 mm NaH2PO4 (pH 7). The absorbance of the dye was measured at 560 nm.

Preparation of HOB Multilayers for Ultrastructural Analysis

Three sets of long-term cultures were processed for ultrastructural examination as follows. After removal from the well the ThermanoxTM coverslips bearing the HOB multilayers were cut into two equal strips and fixed in 2.5% glutaraldehyde in 0.1 m cacodylate buffer, pH 7.2, for 1 h. They were then washed in 0.1 m cacodylate buffer for three changes of 10 min each, after which they were postfixed in 2% aqueous osmium tetroxide for 2 h. Next they were washed in 0.1 m cacodylate buffer for three changes of 10 min each. Dehydration was carried out in 20-min changes of 30, 50, 70, and 90% (v/v) ethanol followed by two changes of water-free absolute ethanol (30 min each) and the two changes of water-free absolute acetone (30 min each). A mixture of 1:1 acetone:Spurr's resin was prepared, and the tissue was transferred to it for 1 h, followed by 3 h in 1:9 acetone:Spurr's resin. The tissue was then left in 100% Spurr's resin overnight. At this stage the coverslips were placed in BEEM capsules filled with Spurr's resin. Curing was carried out at 60 °C for 18 h.

Solubilization of Mineralized HOB Multilayers for Protein Detection

Because sclerostin has been reported to have a basic region, which causes it to bind to bone matrix proteins (32), extraction from the multilayers was tested as well as ELISA, because secreted sclerostin levels might be expected to be low. HOBs were grown to confluence on ThermanoxTM as described previously, and subsequently grown for a further 7, 14, or 28 days in mineralization medium in the presence or absence of strontium. Following treatment the wells were washed with PBS containing 1 mm EDTA. The mineralized matrix was then re-solubilized by the addition of 300 μl of 62.5 mm Tris-HCl, pH 6.8, 5% (w/v) SDS, 10% (v/v) glycerol, 0.25 m DTT, 0.01% (w/v) bromphenol blue, with the protease inhibitors 2 mm PMSF, 1 mm EDTA, 20 μm leupeptin, 2 μm aprotinin, 10 μm pepstatin A, and 50 μm Bestatin·HCl, which had been pre-heated to 95 °C. The resultant slurry was scraped to the bottom of the well and sonicated using the micro-tip of a Branson Sonifier® 250 (Branson Ultrasonics Corp., Danbury, CT) for ∼30 s or until the viscosity of the solution was such that it was able to be freely pipetted. Equal volumes of the sonicated solution were subjected to Western blot analysis and immunoblotting for sclerostin and β-actin as described above.

Sclerostin ELISA

A capture ELISA protocol was designed to measure the level of secreted sclerostin in the dHOB culture media. Unless otherwise stated stages between the ELISA protocol were separated by five washes with PBS, pH 7.4, containing 0.1% (v/v) Tween 20 (PBS-T), and all stages were carried out at room temperature. Briefly, a monoclonal antibody to sclerostin was used to coat a 96-well polystyrene plate overnight at 4 °C at 1 μg/ml in 0.1 m NaHCO3, pH 9. Nonspecific sites of the plate were blocked with 0.1% (w/v) heat-denatured casein (HDC) in PBS-T (HDC/PBS-T). Sclerostin from the supernatants from dHOB cultures or recombinant human sclerostin, at a known concentration, were incubated in the pre-adsorbed wells for 2 h. Bound sclerostin was detected with the addition of a biotinylated polyclonal anti-sclerostin antibody at 0.1 μg/ml in HDC/PBS-T for 1 h. A 1:2000 dilution of streptavidin-HRP conjugate in HDC/PBS-T in HDC-PBS-T was then incubated for 30 min at room temperature. The HRP substrate 3,3′,5,5′-tetramethylbenzidine was added to the wells at 0.1 mg/ml in 50 mm citric acid, 100 mm dibasic sodium phosphate, pH 5.5, containing 0.001% (w/w) H2O2. The colorimetric reaction was stopped by the addition of H2SO4 to a final concentration of 0.7 m, and the absorbance of the wells was measured at 450 nm.

Western Blot Analysis

The phosphorylation status of Akt (Thr308 and Ser473), β-catenin (Ser552), and GSK-3β (Ser9) were analyzed by immunoblotting. At the indicated times following strontium treatment of HOB monolayer cultures the entire cell fraction was solubilized in SDS-lysis buffer (62.5 mm Tris·HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 50 mm DTT, 0.01% (w/v) bromphenol blue with the addition of the abovementioned protease inhibitors in addition to 2.5 mm NaF, 1 mm Na3VO4, 3 mm β-glycerophosphate, and 3 mm sodium pyrophosphate to inhibit phosphatase activity) and briefly sonicated to reduce sample viscosity. Following SDS-PAGE, proteins were transferred electrophoretically to nitrocellulose membranes (GE Healthcare, Piscataway, NJ), and immunoblotting was performed according to the manufacturer's instructions for each antibody. Band densities were measured on a FluorChem SP Digital Imaging System (Alpha Innotech Corp., San Leandro, CA) using an enhanced chemiluminescence substrate (Millipore, Billerica, MA). The intensity of individual bands was determined using the densitometry application of ImageJ (W. Rasband, National Institutes of Health). Each of these experiments was performed at least three times with qualitatively similar results.

Subcellular Localization of β-Catenin

A variation of a previously established sub-cellular fractionation protocol was used to determine the subcellular localization of β-catenin following strontium ranelate treatment of HOB monolayer cultures (33). To isolate the cytosolic fraction HOB monolayers were homogenized in a hypotonic buffer (10 mm Tris (pH 7.5), with the addition of the abovementioned protease inhibitors) following the indicated time of strontium ranelate treatment. Cell lysates were centrifuged for 12,000 × g for 30 min at 4 °C, and the resulting soluble solution represented the non-nuclear fraction. To isolate the nuclear fraction, HOB monolayers were lysed in a detergent buffer (10 mm Tris (pH 7.5), 10 mm NaCl, 3 mm MgCl2, 0.5% (v/v) Nonidet P-40, with the protease inhibitors listed above) for 5 min on ice following the indicated time of strontium ranelate treatment. Cell lysates were centrifuged at 500 × g for 30 min at 4 °C. The pellet was washed two additional times with the same detergent buffer, and the resulting pellet was resuspended in a high salt buffer (10 mm Tris (pH 7.5), 0.4 m NaCl with the protease inhibitors listed above) for 30 min on ice. The lysed nuclear suspension was centrifuged at 12,000 × g for 30 min at 4 °C, and the resulting supernatant represented the nuclear fraction. Protein concentrations from both fractions were normalized using a BCA assay (Pierce), and equal amounts of protein were subjected to Western blot analysis. The presence of β-actin and LaminB1 were used as loading controls for the cytosolic and nuclear fractions, respectively.

Measurement of Caspase Activity

HOBs were seeded in 6-well plates at a density of 1 × 106 cells per well in 10% (v/v) DMEM for 24 h. Following a 24-h period of adaptation to serum-free conditions in Opti-MEMTM containing 1 mm Ca2+, strontium was added to the cells in the absence or presence of 50 nm wortmannin (10 × IC50) for a further 24 h. Oxidative stress was subsequently induced by the addition of 50 μm H2O2, and the level of apoptosis in the cell population was assessed via caspase activity, based on a previously reported protocol utilizing the caspase-3 substrate Ac-DEVD-AFC (34). Protein levels used in the caspase assay for various treatment conditions were normalized following concentration determination by Bradford assay, carried out according to the manufacturer's instructions.

Measurement of Replication

HOBs were seeded in 96-well plates at a density of 7.5 × 103 cells per well in 10% DMEM for 24 h. Following a 24-h period of adaptation to serum-free conditions in Opti-MEMTM containing 1 mm Ca2+, strontium was added to the cells in the absence or presence of 50 nm wortmannin (10 × IC50) for a further 48 h. At this time point HOBs were lysed in PBS, pH 7.4, containing 0.1% (v/v) Triton X-100, and the total cell protein level in the lysates was determined by BCA assay according to the manufacturer's instructions.

Statistics and Data Analysis

Experiments were performed in triplicate. Each experiment was repeated at least three times, and data are given as means ± S.D. One-way analysis of variance with Tukey-Kramer post test to determine significant differences between treatments was performed using InStat version 3.05 (GraphPad).

RESULTS

HOBs Adopted a Multilayered Structure in Long-term Culture under Mineralizing Conditions

When HOB monolayers were cultured on ThermanoxTM under mineralizing conditions the cells grew into an ordered multilayer as described previously (26). The degree of mineralization and depth of the cell multilayer were similar to those observed previously (35). The nature of the mineral has previously been shown by energy-dispersive spectroscopy to be a poorly crystallized form of hydroxyapatite (26). In these structures, type I collagen was organized into layers that ran parallel to (Fig. 1A, P) or perpendicular to (Fig. 1A, T) the plane of the section in a similar fashion to that of skeletal lamellar bone (36), and the HOBs were embedded in the collagen layers (Fig. 1A, O). These cells will henceforth be referred to as differentiated osteoblasts (dHOBs).

FIGURE 1.

FIGURE 1.

A, transmission electron micrograph of the cell multilayer at 20 days post-confluence. In these sections the “osteocyte-like” cell layer (O) can be seen layered with sections of the extracellular matrix. The type I collagen was organized into layers that ran parallel to (P) or perpendicular to (T) the plane of the section. B, strontium (Sr2+) increased HOB mineralization as measured by ARS staining. ARS was measured in HOBs treated in the absence or presence of strontium at the indicated concentration for 7 days (clear bars) or 14 days (black bars) post-confluence. The vehicle treatment contained 1 mm Ca2+. ***, p < 0.001 compared with vehicle; **, p < 0.01 compared with vehicle; *, p < 0.05 compared with vehicle.

Strontium Increases the Mineralization Rate of HOBs

To assess the effect of strontium on the mineralization rate of dHOBs, the cells were permitted to grow to confluence on ThermanoxTM coverslips and then incubated in mineralization media in the absence or presence of strontium at the indicated concentration for 7 or 14 days. In these mature mineralizing cultures, treatment with strontium resulted in a concentration- and time-dependent increase in mineral deposits as measured by ARS staining when compared with the vehicle treatment (Fig. 1B). Significant increases in ARS staining were observed in cultures in which 2 mm strontium was present for 7 (p < 0.01) and 14 days (p < 0.001) of dHOB mineralization when compared with the vehicle treatment. 0.1 mm strontium also induced a significant increase in ARS staining after 14 days of mineralization (p < 0.05).

Strontium Decreased the Expression of Sclerostin in Mineralized HOB Cultures

We were unable to detect sclerostin in monolayer cultures. This marker, localized to osteocytes in adult bone, was reliably detected when mineralized HOB cultures (Fig. 1A) were broken down using a combination of detergent treatment and sonication, and the resultant extractions were analyzed by Western blot for sclerostin protein. When strontium was present during the mineralization of HOBs for 7 or 14 days post-confluence, a concentration- and time-dependent decrease in the level of sclerostin was shown (Fig. 2, A–C). Significant decreases in sclerostin were observed in the presence of 2 mm strontium for 7 (p < 0.05) and 14 days (p < 0.001) when compared with vehicle. In the presence of 0.1 mm strontium a significant reduction in sclerostin was observed after 14 days (p < 0.001). After 14 days the magnitude of the effect of 2 mm strontium was significantly greater than that due to 0.1 mm strontium (p < 0.01). The level of sclerostin secreted into the supernatant of dHOB cultures was measured by capture ELISA. When dHOBs were permitted to mineralize for 14 days and subsequently exposed to medium in the absence or presence of strontium for 3 days, a strontium-induced decrease in secreted sclerostin was detected (Fig. 2D). Thus strontium caused a decrease in the amount of mineral-associated sclerostin (Fig. 2, A–C) as well as secreted sclerostin (Fig. 2D).

FIGURE 2.

FIGURE 2.

Strontium (Sr2+) treatment during HOB mineralization decreased sclerostin expression. In A–C sclerostin protein expression was measured by Western blot (at ∼25 kDa) in HOBs under mineralizing conditions in the absence or presence of strontium at the indicated concentration for 7 (A) and 14 (B) days. C, densitometry of sclerostin Western blot bands from 7 and 14 days normalized to the density of the β-actin bands (clear and filled bars, respectively). The vehicle treatment contained 1 mm Ca2+; ***, p < 0.001 compared with vehicle; **, p < 0.01 compared with vehicle; *, p < 0.05 compared with vehicle. D, exposure to strontium following HOB mineralization decreased sclerostin secretion. HOBs were permitted to mineralize for 14 days and subsequently exposed to strontium at the indicated concentration for 3 days. The level of sclerostin secreted into the media following the 3-day treatment was measured by capture ELISA; ***, p < 0.001 compared with vehicle; **, p < 0.01 compared with vehicle.

Strontium Promoted Canonical Wnt Signaling in HOBs

Canonical Wnt signaling induces a decrease in the ubiquitin-mediated breakdown of the cytosolic pool of β-catenin and its subsequent translocation to the nucleus. Treatment of monolayer HOB cultures with 2 mm strontium resulted in a time-dependent increase in the cytosolic level of β-catenin, with a maximum ∼3-fold increase after 15 min (Fig. 3A). Strontium also induced an increase in the nuclear translocation of β-catenin, with a maximum ∼2-fold increase after 45-min exposure to 2 mm (Fig. 3B).

FIGURE 3.

FIGURE 3.

Strontium (Sr2+) induces cytosolic stabilization and nuclear translocation of β-catenin. HOBs were treated with 2 mm strontium and at the indicated times subcellular fractionation and Western blot analysis were performed to determine the proportion of β-catenin localized to the cytosol (A) or nucleus (B). C, densitometry of β-catenin Western blot bands normalized to the level of β-catenin prior to addition of strontium.

Strontium Activated an Akt-dependent Signaling Cascade in HOBs

The activation of Akt via phosphorylation at Thr308 and Ser473 plays a critical role in the control of cell survival (3739). Akt has been shown previously to phosphorylate β-catenin at Ser552 (15) and GSK-3β at Ser9 (16) resulting in β-catenin accumulation in the nucleus and increases in its transcriptional activity. Treatment of monolayer HOB cultures with 0.1 or 2 mm strontium resulted in the phosphorylation of Akt at Thr308 and Ser473 as well as β-catenin phosphorylation at Ser552 and GSK-3β at Ser9 (Fig. 4A).

FIGURE 4.

FIGURE 4.

Strontium (Sr2+) activates an Akt-dependent signaling cascade that modulates canonical Wnt signaling via the CaSR. Akt, β-catenin and GSK-3β were phosphorylated in response to strontium. Western blots of total Akt and Akt phosphorylated at Thr308 and Ser473, total β-catenin, and β-catenin phosphorylated at Ser552 and total GSK-3β and GSK-3β phosphorylated at Ser9 over 60 min in HOBs following 0.1 (A, left) or 2 (A, right) mm strontium. B, Western blot of total Akt and Akt phosphorylated at Thr308 and Ser473 in HOBs following 10-min exposure to 2 mm strontium in the absence (−W) or presence (+W) of 50 nm (10 × IC50) wortmannin. C, Western blot of total Akt and Akt phosphorylated at Thr308 and Ser473 in HOBs following 10-min exposure to 2 mm strontium in the absence (−NPS) or presence (+NPS) of the calcilytic NPS2143 at 500 nm. D, Western blot of total GSK-3β and GSK-3β phosphorylated at Ser9, total β-catenin and β-catenin phosphorylated at Ser552, LaminB1 and nuclear localized β-catenin in HOBs following 10-min exposure to 2 mm strontium treatment in the absence (−AKTXI) or presence (+AKTXI) of an AKT kinase inhibitor at 1 μm.

Strontium-induced Akt-Thr308 Phosphorylation in HOBs Is PI3K-dependent

Activation of Class I PI3Ks results from the activation of receptor tyrosine kinases and G-protein-coupled receptors (37), and it is the regulatory kinase responsible for phosphorylation of Akt at Thr308 via PDK1 (40). Wortmannin was utilized as a specific inhibitor of PI3K to determine whether strontium-induced Akt phosphorylation was PI3K-dependent. Pre-treatment of HOBs with 50 nm (10 × IC50) wortmannin for 5 min abolished the effect of 2 mm strontium on Akt-Thr308 phosphorylation and modestly decreased Akt Ser473 phosphorylation (Fig. 4B).

Calcilytic NPS2143 Decreased Strontium-induced Akt Phosphorylation in HOBs

NPS2143 is a calcilytic that stimulates parathyroid hormone secretion by antagonizing CaSRs on parathyroid cells (41). We utilized NPS2143 to determine whether the CaSR is involved in strontium-induced Akt phosphorylation in HOBs. Akt phosphorylation was measured in HOBs that were pre-treated with 500 nm (10 × IC50) NPS2143 for 5 min followed by the addition of 2 mm strontium for 10 min. The level of strontium-induced phosphorylation of Akt at Thr308 and Ser473 was decreased in the presence of NPS2143 (Fig. 4C).

Akt-Thr308 Phosphorylation in HOBs Is Critical for Strontium-induced Increases in Replication but Not for Strontium-induced Inhibition of Apoptosis

We have previously shown that strontium promotes cell replication and inhibits apoptosis induced by serum deprivation in HOBs (21). In the current study pre-treatment of HOBs with 50 nm wortmannin abolished strontium-induced Akt-Thr308 phosphorylation but had little effect on strontium-induced Akt-Ser473 phosphorylation (Fig. 4B). In addition, wortmannin abolished strontium-induced increases in HOB replication (Fig. 5A). The findings indicate that Akt-Thr308 phosphorylation is required for strontium-induced replication in HOBs.

FIGURE 5.

FIGURE 5.

Wortmannin had differential effects on strontium-induced replication and survival in HOBs. A, strontium (Sr2+) promoted HOB replication, and this was inhibited by wortmannin. BCA assay measured the total cell protein (t.c.p.) of HOBs that were treated with 2 mm strontium or vehicle for 48 h in the absence (clear bars) or presence (black bars) of 50 nm (10 × IC50) wortmannin. B, strontium decreased caspase-3 activation following oxidative stress, and this was not reversed by wortmannin. The level of caspase-3 activation was determined in HOBs that had been cultured for 24 h in the presence of 2 mm strontium or vehicle in the absence (clear bars) or presence (black bars) of 50 nm wortmannin and then exposed to 50 μm H2O2 for 2.5 h; ***, p < 0.001 compared with vehicle.

In addition to its effect on cell replication, strontium promoted survival in HOBs exposed to oxidative stress. Thus, treatment with 2 mm strontium for 24 h decreased the level of activated caspase-3 following 2.5-h exposure to 50 μm H2O2 (Fig. 5B). Unlike the effect of strontium on cell replication, 50 nm wortmannin had no effect on strontium-induced suppression of caspase-3 activation (Fig. 5B).

Akt Kinase Inhibition Decreased Strontium-dependent Canonical Wnt Signaling in HOBs

AKT-XI is a cell-permeable copper complex that interacts with both the PH and kinase domains of Akt and potently inhibits its kinase activity (42). We utilized AKT-XI to determine whether strontium-induced phosphorylation of GSK-3β at Ser9, β-catenin at Ser552 (Fig. 4A), and/or β-catenin translocation to the nucleus (Fig. 3B) lie downstream of AKT kinase as previously described (15, 16). Phosphorylation of GSK-3β-Ser9, β-catenin-Ser552, and β-catenin nuclear translocation were determined in HOBs pre-treated with 1 μm AKT-XI for 5 min then exposed to 2 mm strontium for 10 min (Fig. 4D). AKT-XI substantially decreased the levels of phosphorylated GSK-3β and β-catenin and reduced the nuclear translocation of β-catenin. Thus, Akt-dependent kinase activity is required for all of these events.

DISCUSSION

In addition to a role in cell adhesion (43), β-catenin is a highly conserved component of the canonical Wnt signaling pathway (44). The nuclear translocation of β-catenin is induced by extracellular Wnt proteins but also occurs in response to other stimuli, including oxidative stress (34). Here we show that strontium induces canonical Wnt signaling in HOBs (Fig. 3) and provide evidence that two candidate pathways are involved. The first is an Akt-dependent mechanism (Fig. 4) previously described for canonical Wnt signaling (15, 16). The second arises from a strontium-induced decrease in the protein expression of sclerostin (Fig. 2), a known antagonist of canonical Wnt signaling, in dHOB multilayers.

The activation of Akt is modulated via PI3K-induced phosphorylation at Thr308 (38) and via mTORC2-induced phosphorylation at Ser473 (17). Our findings demonstrate that strontium induces phosphorylation at both of these sites in HOBs (Fig. 4A). Dual-phosphorylation of Akt may explain the pro-survival effect of strontium that was previously reported (21). Knock-out mouse studies have shown that of the three isoforms of Akt, Akt1 regulates the control of osteoblast survival (45), whereas Akt2 promotes induction of differentiation prior to Runx2 expression (46). Here we show that strontium induces the phosphorylation of Akt at Thr308 in HOBs in a PI3K-dependent manner (Fig. 4B). Interestingly, strontium-induced phosphorylation of Akt at Ser473 was relatively unaffected by wortmannin (Fig. 4B) distinct from its effects on Akt-Ser473 phosphorylation in some cell lines (38, 47). The results suggest that Akt signaling mechanisms may be differentially regulated in native cells.

We and others have previously reported that the CaSR is required for strontium-induced responses in HOBs (21, 48). In the current study, the finding that the calcilytic NPS2143 prevented strontium-induced phosphorylation of Akt at Thr308 as well as Ser473 (Fig. 4C) provides additional evidence that the CaSR mediates key elements of the strontium response, including the activation of PI3K and PDK1 (Akt-T308) and mTORC2 (Akt-Ser473). Wortmannin did not affect strontium-induced Akt-Ser473 phosphorylation (Fig. 4B). This finding implies that the CaSR-dependent activation of mTORC2, unlike PDK1, is independent of PI3K in HOBs. The differential effects of wortmannin on strontium-induced replication (inhibited) and on strontium-induced decreases in caspase activity after oxidative stress (no effect) (Fig. 5) are consistent with the proposal that stimulation of replication was dependent on phosphorylation of Akt at Thr308, but that protection from stress-induced apoptosis requires phosphorylation at Ser473, an mTORC2-dependent process (17). In regards to strontium-induced activation of mTOR complexes, it is relevant that we have also observed strontium-induced phosphorylation of mTOR at Ser2448, a marker of mTOR complex 1 activity (data not shown), however this is known to be a downstream element of Akt (18). We are currently investigating the activation of mTOR complexes by strontium in HOBs.

The phosphorylation of β-catenin at Ser552 by Akt has been shown to release β-catenin from cell-cell contacts leading to its accumulation in both the cytosol and the nucleus followed by an increase in its transcriptional activity (15). Here we found that β-catenin is phosphorylated at Ser552 by Akt in response to strontium (Fig. 4A). β-Catenin nuclear translocation was further promoted by Akt-dependent phosphorylation of GSK-3β at Ser9 (Fig. 4A), which alleviates constitutive breakdown of β-catenin, in the cytoplasm (16). Therefore, strontium promoted nuclear translocation of β-catenin via two Akt-dependent signaling mechanisms: direct phosphorylation of β-catenin at Ser552; and decreased constitutive breakdown of β-catenin via phosphorylation of GSK-3β at Ser9. AKT-XI, an inhibitor of Akt-kinase decreased strontium-induced phosphorylation of GSK-3β-Ser9 and β-catenin-Ser552 and suppressed strontium-induced β-catenin nuclear translocation in HOBs (Fig. 4D).

A recent study in murine MC3T3-E1 cells reported that strontium promoted calcineurin-mediated nuclear factor of activated T-cells (NFAT) signaling resulting in enhanced transcriptional activity of β-catenin (49). Here we found that strontium induced PI3K-mediated activation of Akt in HOBs (Fig. 4B). Because the nuclear factor of activated T-cell signaling is mediated, at least in part by GSK-3 activity (50), and Akt is recognized as a modulator of GSK-3β (15), activation of both signaling pathways may arise in response to strontium in HOBs.

The level of strontium-induced phosphorylation was greater for all proteins investigated in the presence of 2 mm when compared with 0.1 mm (Fig. 4A). Such an increase in Akt-dependent signaling may explain the increased effectiveness of strontium ranelate when used in studies at doses yielding serum concentrations higher than the ∼0.1 mm typically seen in patients on standard therapy (29, 51). Consistent with this, variations in the activation of intracellular signaling cascades and expression of sclerostin (Figs. 2 and 4) were dependent on the strontium concentration. The use of higher concentrations of strontium (2 mm) in the current study, than are commonly observed in the blood of patients (51), may also be pharmacologically relevant at sites of bone remodeling where strontium can accumulate (30).

To assess the effect of strontium on HOB differentiation we employed an established protocol that promotes the adoption of an “osteocyte-like” phenotype (Fig. 1A) (26). We and others have previously shown that strontium induces differentiation of osteoblasts, as measured by increases in alkaline phosphatase activity and RUNX2 mRNA expression (21, 22), as well as osteocalcin (23). Here we found that strontium induced an increase in mineralization of dHOBs in a time- and concentration-dependent manner (Fig. 1B). This mineral was shown to be an immature form of hydroxyapatite by energy-dispersive spectroscopy (26). The expression of the osteocyte-derived sclerostin protein (9) as early as 7 days post-confluence supports the notion that the mineralizing culture conditions had induced differentiation of HOBs to an osteocyte-like phenotype (Fig. 2A).

We evaluated sclerostin protein expression, because an earlier study on the effect of strontium on sclerostin mRNA expression reported variable results (23). Furthermore, discordant correlations between the levels of mRNA and protein have been observed (5254), and the correlations between mRNA and secreted protein levels for various human genes are low (52, 55). Because the primary structure of sclerostin is known to contain a positively charged basic region (32), it is likely that this region strongly interacts with negatively charged proteoglycans present in dHOB multilayer cultures (56). For this reason we measured the level of sclerostin extracted from the dHOB multilayer. We have previously identified other secreted proteins, including insulin-like growth factors I and II, transforming growth factor-β1, and basic fibroblast growth factor associated with cultured dHOB multilayers (56). This could also be the reason for the relatively low level of secreted sclerostin. Despite detection levels for the ELISA as low as 150 pg/ml, dHOB supernatant levels were frequently below threshold. Where levels of sclerostin were detected by ELISA a statistically significant strontium-dependent decrease in the level of the protein was observed (Fig. 2D). In these osteocyte-like cells, strontium induced a time- and concentration-dependent decrease in sclerostin protein expression, following 7 or 14 days of mineralization (Fig. 2). Because sclerostin disrupts the Frizzled/LRP complex (57), a decrease in sclerostin expression promotes canonical Wnt signaling. This finding is of particular significance for osteoblasts, because Wnts have been shown to repress alternative differentiation pathways (e.g. adipocytes) and promote osteoblast survival, differentiation, proliferation, and mineralization (58).

In conclusion, strontium promotes canonical Wnt signaling in HOBs at pharmacologically relevant concentrations. This effect occurs at least in part via activation of an Akt-dependent signaling mechanism (Fig. 6). In an apparently separate process, strontium also suppressed sclerostin expression, an effect that would be expected to increase canonical Wnt signaling (Fig. 6). Taken together these findings provide a molecular mechanism for the increased bone formation rates seen with strontium ranelate treatment in vivo (3).

FIGURE 6.

FIGURE 6.

Strontium (Sr2+) promotes canonical Wnt signaling in HOBs via two independent signaling pathways. In the absence of strontium canonical Wnt signaling operates at a basal level via the interaction of extracellular canonical Wnt proteins with the Frizzled/LRP complex leading to the translocation of β-catenin to the nucleus. Strontium has also been reported to increase the secretion of canonical Wnts from osteoblasts (49). Sclerostin expression by osteocytes into the cellular environment disrupts the Wnt-Frizzled/LRP complex and thus inhibits Wnt signaling. Strontium activates Akt (via phosphorylation at Thr308 and Ser473), inhibits GSK-3β (via phosphorylation at Ser9), and promotes phosphorylation of β-catenin at Ser552 to promote β-catenin translocation to the nucleus. Strontium also suppresses the expression of sclerostin by osteocyte-like cells further promoting canonical Wnt signaling via a decrease in the level of disruption of the Wnt-Frizzled/LRP complex formation by sclerostin. Inhibitors used in this study are highlighted in italics at their sites of action in the signaling cascade.

Acknowledgment

Dr. Arthur Christopoulos, Monash Institute of Pharmacology, Monash University, Victoria, Australia, kindly provided the NPS2143 calcilytic.

*

This work was supported by the National Health and Medical Research Council of Australia (Grant 21124 to A. D. C. and R. S. M.) and by Servier, France. The research project was funded by Servier, France, which markets strontium ranelate as an agent for the treatment of osteoporosis. The research proposal originated from the authors group. Servier had no input into the conduct of the research, analysis of data, or preparation of this manuscript.

2
The abbreviations used are:
GSK-3β
glycogen synthase kinase-3β
mTOR
mammalian target of rapamycin
mTORC1
mTOR complex 1
mTORC2
mTOR complex 2
BCA
bicinchoninic acid
HOB
human osteoblast
ARS
Alizarin Red S
HDC
heat-denatured casein
dHOB
differentiated osteoblast
CaSR
calcium-sensing receptor.

REFERENCES

  • 1. Meunier P. J., Roux C., Ortolani S., Diaz-Curiel M., Compston J., Marquis P., Cormier C., Isaia G., Badurski J., Wark J. D., Collette J., Reginster J. Y. (2009) Osteoporos. Int. 20, 1663–1673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Meunier P. J., Slosman D. O., Delmas P. D., Sebert J. L., Brandi M. L., Albanese C., Lorenc R., Pors-Nielsen S., De Vernejoul M. C., Roces A., Reginster J. Y. (2002) J. Clin. Endocrinol. Metab. 87, 2060–2066 [DOI] [PubMed] [Google Scholar]
  • 3. Arlot M. E., Jiang Y., Genant H. K., Zhao J., Burt-Pichat B., Roux J. P., Delmas P. D., Meunier P. J. (2008) J. Bone Miner. Res. 23, 215–222 [DOI] [PubMed] [Google Scholar]
  • 4. Reginster J. Y., Bruyere O., Sawicki A., Roces-Varela A., Fardellone P., Roberts A., Devogelaer J. P. (2009) Bone 45, 1059–1064 [DOI] [PubMed] [Google Scholar]
  • 5. Reginster J. Y., Deroisy R., Dougados M., Jupsin I., Colette J., Roux C. (2002) Osteoporos. Int. 13, 925–931 [DOI] [PubMed] [Google Scholar]
  • 6. Boivin G., Farlay D., Khebbab M. T., Jaurand X., Delmas P. D., Meunier P. J. (2009) Osteoporos. Int. 21, 667–677 [DOI] [PubMed] [Google Scholar]
  • 7. Winkler D. G., Sutherland M. K., Geoghegan J. C., Yu C., Hayes T., Skonier J. E., Shpektor D., Jonas M., Kovacevich B. R., Staehling-Hampton K., Appleby M., Brunkow M. E., Latham J. A. (2003) EMBO J. 22, 6267–6276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Lin C., Jiang X., Dai Z., Guo X., Weng T., Wang J., Li Y., Feng G., Gao X., He L. (2009) J. Bone Miner. Res. 24, 1651–1661 [DOI] [PubMed] [Google Scholar]
  • 9. van Bezooijen R. L., Roelen B. A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., Hamersma H., Papapoulos S. E., ten Dijke P., Löwik C. W. (2004) J. Exp. Med. 199, 805–814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Kusu N., Laurikkala J., Imanishi M., Usui H., Konishi M., Miyake A., Thesleff I., Itoh N. (2003) J. Biol. Chem. 278, 24113–24117 [DOI] [PubMed] [Google Scholar]
  • 11. Kubota T., Michigami T., Ozono K. (2009) J. Bone Miner. Metab. 27, 265–271 [DOI] [PubMed] [Google Scholar]
  • 12. Semënov M., Tamai K., He X. (2005) J. Biol. Chem. 280, 26770–26775 [DOI] [PubMed] [Google Scholar]
  • 13. Behrens J., von Kries J. P., Kühl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W. (1996) Nature 382, 638–642 [DOI] [PubMed] [Google Scholar]
  • 14. Choi H. Y., Dieckmann M., Herz J., Niemeier A. (2009) PLoS One 4, e7930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Fang D., Hawke D., Zheng Y., Xia Y., Meisenhelder J., Nika H., Mills G. B., Kobayashi R., Hunter T., Lu Z. (2007) J. Biol. Chem. 282, 11221–11229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Cross D. A., Alessi D. R., Cohen P., Andjelkovich M., Hemmings B. A. (1995) Nature 378, 785–789 [DOI] [PubMed] [Google Scholar]
  • 17. Sarbassov D. D., Guertin D. A., Ali S. M., Sabatini D. M. (2005) Science 307, 1098–1101 [DOI] [PubMed] [Google Scholar]
  • 18. Nave B. T., Ouwens M., Withers D. J., Alessi D. R., Shepherd P. R. (1999) Biochem. J. 344, 427–431 [PMC free article] [PubMed] [Google Scholar]
  • 19. Fang Y., Vilella-Bach M., Bachmann R., Flanigan A., Chen J. (2001) Science 294, 1942–1945 [DOI] [PubMed] [Google Scholar]
  • 20. Hay N., Sonenberg N. (2004) Genes Dev. 18, 1926–1945 [DOI] [PubMed] [Google Scholar]
  • 21. Brennan T. C., Rybchyn M. S., Green W., Atwa S., Conigrave A. D., Mason R. S. (2009) Br. J. Pharmacol. 157, 1291–1300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Bonnelye E., Chabadel A., Saltel F., Jurdic P. (2008) Bone 42, 129–138 [DOI] [PubMed] [Google Scholar]
  • 23. Atkins G. J., Welldon K. J., Halbout P., Findlay D. M. (2009) Osteoporos. Int. 20, 653–664 [DOI] [PubMed] [Google Scholar]
  • 24. Buehler J., Chappuis P., Saffar J. L., Tsouderos Y., Vignery A. (2001) Bone 29, 176–179 [DOI] [PubMed] [Google Scholar]
  • 25. Kiel D. P., Ferrari S. L., Cupples L. A., Karasik D., Manen D., Imamovic A., Herbert A. G., Dupuis J. (2007) Bone 40, 587–596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Slater M., Patava J., Mason R. S. (1994) J. Bone Miner. Res. 9, 161–169 [DOI] [PubMed] [Google Scholar]
  • 27. Bowers G. N., Jr., Brassard C., Sena S. F. (1986) Clin. Chem. 32, 1437–1447 [PubMed] [Google Scholar]
  • 28. Blake G. M., Fogelman I. (2005) J. Bone Miner. Res. 20, 1901–1904 [DOI] [PubMed] [Google Scholar]
  • 29. Coulombe J., Faure H., Robin B., Ruat M. (2004) Biochem. Biophys. Res. Commun. 323, 1184–1190 [DOI] [PubMed] [Google Scholar]
  • 30. Dahl S. G., Allain P., Marie P. J., Mauras Y., Boivin G., Ammann P., Tsouderos Y., Delmas P. D., Christiansen C. (2001) Bone 28, 446–453 [DOI] [PubMed] [Google Scholar]
  • 31. Stanford C. M., Jacobson P. A., Eanes E. D., Lembke L. A., Midura R. J. (1995) J. Biol. Chem. 270, 9420–9428 [DOI] [PubMed] [Google Scholar]
  • 32. Veverka V., Henry A. J., Slocombe P. M., Ventom A., Mulloy B., Muskett F. W., Muzylak M., Greenslade K., Moore A., Zhang L., Gong J., Qian X., Paszty C., Taylor R. J., Robinson M. K., Carr M. D. (2009) J. Biol. Chem. 284, 10890–10900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Shin S. Y., Kim C. G., Jho E. H., Rho M. S., Kim Y. S., Kim Y. H., Lee Y. H. (2004) Cancer Lett. 212, 225–231 [DOI] [PubMed] [Google Scholar]
  • 34. Grebenová D., Kuzelová K., Smetana K., Pluskalová M., Cajthamlová H., Marinov I., Fuchs O., Soucek J., Jarolím P., Hrkal Z. (2003) J. Photochem. Photobiol. B 69, 71–85 [DOI] [PubMed] [Google Scholar]
  • 35. Slater M., Patava J., Kingham K., Mason R. S. (1995) J. Orthop. Res. 13, 655–663 [DOI] [PubMed] [Google Scholar]
  • 36. Malluche H. H., Faugere M. C. (eds) (1986) Atlas of Mineralized Bone Histology, pp. 10–11, S. Karger, New York [Google Scholar]
  • 37. Burgering B. M., Coffer P. J. (1995) Nature 376, 599–602 [DOI] [PubMed] [Google Scholar]
  • 38. Franke T. F., Yang S. I., Chan T. O., Datta K., Kazlauskas A., Morrison D. K., Kaplan D. R., Tsichlis P. N. (1995) Cell 81, 727–736 [DOI] [PubMed] [Google Scholar]
  • 39. Franke T. F., Kaplan D. R., Cantley L. C. (1997) Cell 88, 435–437 [DOI] [PubMed] [Google Scholar]
  • 40. Alessi D. R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B. A. (1996) EMBO J. 15, 6541–6551 [PMC free article] [PubMed] [Google Scholar]
  • 41. Nemeth E. F. (2002) J. Mol. Endocrinol. 29, 15–21 [DOI] [PubMed] [Google Scholar]
  • 42. Barve V., Ahmed F., Adsule S., Banerjee S., Kulkarni S., Katiyar P., Anson C. E., Powell A. K., Padhye S., Sarkar F. H. (2006) J. Med. Chem. 49, 3800–3808 [DOI] [PubMed] [Google Scholar]
  • 43. Ozawa M., Baribault H., Kemler R. (1989) EMBO J. 8, 1711–1717 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Willert K., Nusse R. (1998) Curr. Opin. Genet. Dev. 8, 95–102 [DOI] [PubMed] [Google Scholar]
  • 45. Kawamura N., Kugimiya F., Oshima Y., Ohba S., Ikeda T., Saito T., Shinoda Y., Kawasaki Y., Ogata N., Hoshi K., Akiyama T., Chen W. S., Hay N., Tobe K., Kadowaki T., Azuma Y., Tanaka S., Nakamura K., Chung U. I., Kawaguchi H. (2007) PLoS One 2, e1058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Mukherjee A., Wilson E. M., Rotwein P. (2010) Mol. Cell Biol. 30, 1018–1027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S., Russo G., Tsichlis P., Croce C. M. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 3028–3033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Chattopadhyay N., Quinn S. J., Kifor O., Ye C., Brown E. M. (2007) Biochem. Pharmacol. 74, 438–447 [DOI] [PubMed] [Google Scholar]
  • 49. Fromigué O., Haÿ E., Barbara A., Marie P. J. (2009) J. Biol. Chem. 285, 25251–25258 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Crabtree G. R., Olson E. N. (2002) Cell 109, Suppl., S67–S79 [DOI] [PubMed] [Google Scholar]
  • 51. Meunier P. J., Roux C., Seeman E., Ortolani S., Badurski J. E., Spector T. D., Cannata J., Balogh A., Lemmel E. M., Pors-Nielsen S., Rizzoli R., Genant H. K., Reginster J. Y. (2004) N. Engl. J. Med. 350, 459–468 [DOI] [PubMed] [Google Scholar]
  • 52. Anderson L., Seilhamer J. (1997) Electrophoresis 18, 533–537 [DOI] [PubMed] [Google Scholar]
  • 53. Pascal L. E., True L. D., Campbell D. S., Deutsch E. W., Risk M., Coleman I. M., Eichner L. J., Nelson P. S., Liu A. Y. (2008) BMC Genomics 9, 246 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Chen G., Gharib T. G., Huang C. C., Taylor J. M., Misek D. E., Kardia S. L., Giordano T. J., Iannettoni M. D., Orringer M. B., Hanash S. M., Beer D. G. (2002) Mol. Cell Proteomics 1, 304–313 [DOI] [PubMed] [Google Scholar]
  • 55. Lichtinghagen R., Musholt P. B., Lein M., Römer A., Rudolph B., Kristiansen G., Hauptmann S., Schnorr D., Loening S. A., Jung K. (2002) Eur. Urol. 42, 398–406 [DOI] [PubMed] [Google Scholar]
  • 56. Slater M., Patava J., Kingham K., Mason R. S. (1994) Am. J. Physiol. 267, E990–E1001 [DOI] [PubMed] [Google Scholar]
  • 57. Li X., Zhang Y., Kang H., Liu W., Liu P., Zhang J., Harris S. E., Wu D. (2005) J. Biol. Chem. 280, 19883–19887 [DOI] [PubMed] [Google Scholar]
  • 58. Krishnan V., Bryant H. U., Macdougald O. A. (2006) J. Clin. Invest. 116, 1202–1209 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES